Prestige Consumer Healthcare Beheer
Beheer criteriumcontroles 4/4
De CEO Prestige Consumer Healthcare is Ron Lombardi, benoemd in Jun2015, heeft een ambtstermijn van 9.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.76M, bestaande uit 17.4% salaris en 82.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde $ 30.67M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.3 jaar en 4.5 jaar.
Belangrijke informatie
Ron Lombardi
Algemeen directeur
US$5.8m
Totale compensatie
| Percentage CEO-salaris | 17.4% |
| Dienstverband CEO | 9.4yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 7.3yrs |
| Gemiddelde ambtstermijn bestuur | 4.5yrs |
Recente managementupdates
Recent updates
We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Nov 03
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Popularity With Investors Is Under Threat From Overpricing
Sep 10Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Jul 16Revenues Not Telling The Story For Prestige Consumer Healthcare Inc. (NYSE:PBH)
May 22Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 26An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 50% Undervalued
Mar 05Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Feb 11Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Shares May Have Run Too Fast Too Soon
Feb 05Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Dec 14Prestige Consumer Healthcare (NYSE:PBH) Seems To Use Debt Quite Sensibly
Sep 10Prestige Consumer Healthcare: Unproductive Buyback And Excessive Valuation
Aug 15Is Prestige Consumer Healthcare (NYSE:PBH) Using Too Much Debt?
Jun 12An Intrinsic Calculation For Prestige Consumer Healthcare Inc. (NYSE:PBH) Suggests It's 43% Undervalued
May 20Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has Caught The Eye Of Investors
Mar 17Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Mar 02Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Intrinsic Value Is Potentially 75% Above Its Share Price
Feb 08Prestige Consumer Healthcare reports Q3 earnings beat; updates FY23 guidance
Feb 02Prestige Consumer Healthcare: Taking My Winnings Off The Table
Jan 19Here's Why Prestige Consumer Healthcare (NYSE:PBH) Can Manage Its Debt Responsibly
Nov 23Prestige Consumer Healthcare GAAP EPS of $1.02 beats by $0.02, revenue of $289.3M beats by $6.07M
Nov 03Holding Prestige Consumer Healthcare
Aug 31If EPS Growth Is Important To You, Prestige Consumer Healthcare (NYSE:PBH) Presents An Opportunity
Aug 26We Think Prestige Consumer Healthcare (NYSE:PBH) Can Stay On Top Of Its Debt
Aug 05Prestige Consumer Healthcare GAAP EPS of $1.09 beats by $0.05, revenue of $277.1M beats by $8.18M
Aug 04Should You Be Adding Prestige Consumer Healthcare (NYSE:PBH) To Your Watchlist Today?
May 27Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
May 05Does Prestige Consumer Healthcare (NYSE:PBH) Deserve A Spot On Your Watchlist?
Feb 22Is Prestige Consumer Healthcare (NYSE:PBH) A Risky Investment?
Feb 03These 4 Measures Indicate That Prestige Consumer Healthcare (NYSE:PBH) Is Using Debt Extensively
Nov 04Here's Why Prestige Consumer Healthcare (NYSE:PBH) Has A Meaningful Debt Burden
Aug 06Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$206m |
| Jun 30 2024 | n/a | n/a | US$205m |
| Mar 31 2024 | US$6m | US$1m | US$209m |
| Dec 31 2023 | n/a | n/a | -US$81m |
| Sep 30 2023 | n/a | n/a | -US$82m |
| Jun 30 2023 | n/a | n/a | -US$84m |
| Mar 31 2023 | US$6m | US$1m | -US$82m |
| Dec 31 2022 | n/a | n/a | US$210m |
| Sep 30 2022 | n/a | n/a | US$209m |
| Jun 30 2022 | n/a | n/a | US$203m |
| Mar 31 2022 | US$6m | US$937k | US$205m |
| Dec 31 2021 | n/a | n/a | US$189m |
| Sep 30 2021 | n/a | n/a | US$179m |
| Jun 30 2021 | n/a | n/a | US$179m |
| Mar 31 2021 | US$5m | US$888k | US$165m |
| Dec 31 2020 | n/a | n/a | US$166m |
| Sep 30 2020 | n/a | n/a | US$163m |
| Jun 30 2020 | n/a | n/a | US$152m |
| Mar 31 2020 | US$5m | US$875k | US$142m |
| Dec 31 2019 | n/a | n/a | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$34m |
| Jun 30 2019 | n/a | n/a | -US$36m |
| Mar 31 2019 | US$4m | US$850k | -US$36m |
| Dec 31 2018 | n/a | n/a | US$64m |
| Sep 30 2018 | n/a | n/a | US$340m |
| Jun 30 2018 | n/a | n/a | US$340m |
| Mar 31 2018 | US$4m | US$850k | US$340m |
Compensatie versus markt: De totale vergoeding ($USD 5.76M ) Ron } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.57M ).
Compensatie versus inkomsten: De vergoeding van Ron is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ron Lombardi (60 yo)
9.4yrs
Tenure
US$5,763,133
Compensatie
Mr. Ronald M. Lombardi, also known as Ron, served as a Director at Consumer Healthcare Products Association. He has been the Chief Executive Officer and President of Prestige Brands Holdings, Inc. (now Pre...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 9.4yrs | US$5.76m | 0.75% $ 30.7m | |
| Chief Financial Officer | 8.2yrs | US$2.00m | 0.036% $ 1.5m | |
| Senior Vice President of Operations | 6.6yrs | US$862.93k | 0.064% $ 2.6m | |
| Senior VP | 8yrs | US$1.34m | 0.026% $ 1.1m | |
| Executive Vice President of Marketing & Sales | 5.5yrs | US$1.32m | 0.024% $ 1.0m | |
| Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Director of Communications | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Quality & Regulatory Affairs | 6.4yrs | geen gegevens | 0.030% $ 1.2m |
7.3yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PBH is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 9.4yrs | US$5.76m | 0.75% $ 30.7m | |
| Lead Independent Director | 18.8yrs | US$273.33k | 0.097% $ 4.0m | |
| Independent Director | 3.8yrs | US$257.08k | 0.014% $ 573.9k | |
| Independent Director | 4.5yrs | US$260.63k | 0.020% $ 821.8k | |
| Independent Director | 9.3yrs | US$243.33k | 0.048% $ 1.9m | |
| Independent Director | 1.3yrs | US$197.92k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
4.5yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PBH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.5 jaar).